A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

13 Feb 2025 Status changed from planning to recruiting.
10 Feb 2025 Status changed from recruiting to completed, According to a CLINUVEL media release.
10 Feb 2025 According to a CLINUVEL media release, Final analyses of data from CUV052 are expected in the second half of 2025, with a further submission to the EMA planned to seek expansion of the SCENESSE label. company is facilitating limited special access to SCENESSE treatment for patients enrolled in the CUV052 study, with all eligible enrolled patients electing to receive further treatment in 2024 or 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com